Abstract
HIV-associated Kaposi’s sarcoma (KS), which is caused by Kaposi’s sarcoma-associated herpesvirus, usually arises in the context of uncontrolled HIV replication and immunosuppression. However, disease occasionally persists in individuals with durable HIV viral suppression and CD4 T cell recovery under anti-retroviral therapy (ART). The underlying mechanisms associated with this persistence are unclear. Suppression of viral infections can be mediated by CD8 T cells that detect infected cells via their T cell receptor and the CD8 co-receptor. However, CD8 T cells exhibit signs of functional exhaustion in untreated HIV infection that may not be fully reversed under ART. To investigate whether persistent KS under ART was associated with phenotypic and functional perturbations of CD8 T cells, we performed a cross-sectional study comparing HIV-infected individuals with persistent KS under effective ART (HIV+ KS+) to HIV-infected individuals receiving effective ART with no documented history of KS (HIV+ KSneg). A subset of T cells with low cell surface expression of CD8 (“CD8dim T cells”) was expanded in HIV+ KS+ compared with HIV+ KSneg participants. Relative to CD8bright T cells, CD8dim T cells exhibited signs of senescence (CD57) and mitochondrial perturbations (PGC-1α, MitoTracker) ex vivo. Mitochondrial activity (MitoTracker) was also reduced in proliferating CD8dim T cells. These findings indicate that an expanded CD8dim T cell population displaying features of senescence and mitochondrial dysfunction is associated with KS persistence under ART. CD8 co-receptor down-modulation may be symptomatic of ongoing disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by a Young Investigator Pilot Award awarded to G.T.C. by the AIDS and Cancer Specimen Resource, funded by the National Cancer Institute (UM1 CA181255). Initial sample collection was supported by NIH grants U01 AI117844, U01 AI095052, and R01 HL132791. The UNC Flow Cytometry Core Facility is supported in part by P30 CA016086 Cancer Center Core Support Grant to the UNC Lineberger Comprehensive Cancer Center and by the Center for AIDS Research award number 5P30AI050410. Statistical expertise was provided by the University of North Carolina at Chapel Hill Center for AIDS Research, an NIH funded program P30 AI050410. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study of participants with KS was approved by the Institutional Review Board of the University of California, San Francisco (approval no. 10-02850). Initial collection of UNC samples was approved by the UNC Institutional Review Board (ethics numbers 11-0228; 14-0741; and 15-1626). Retrospective use of all samples was approved by the UNC Institutional Review Board (ethics number 17-2415).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: This study was supported by a Young Investigator Pilot Award awarded to G.T.C. by the AIDS and Cancer Specimen Resource, funded by the National Cancer Institute (UM1 CA181255). Initial sample collection was supported by NIH grants U01 AI117844, U01 AI095052, and R01 HL132791. The UNC Flow Cytometry Core Facility is supported in part by P30 CA016086 Cancer Center Core Support Grant to the UNC Lineberger Comprehensive Cancer Center and by the Center for AIDS Research award number 5P30AI050410. Statistical expertise was provided by the University of North Carolina at Chapel Hill Center for AIDS Research, an NIH funded program P30 AI050410. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
Abbreviations used in this article
- ART
- (HIV) Anti-retroviral therapy
- CFSE
- carboxyfluorescein succinimidyl ester
- KS
- Kaposi’s sarcoma
- KSHV
- Kaposi’s sarcoma-associated herpesvirus, also known as HHV-8
- MTDR
- MitoTracker® Deep Red
- PBMC
- Peripheral blood mononuclear cells
- PHA
- Phytohaemagglutinin
- TCR
- T cell receptor
